Q2 Earnings Forecast for OKYO Pharma Issued By HC Wainwright

OKYO Pharma Limited (NASDAQ:OKYO) – Stock analysts at HC Wainwright dropped their Q2 2025 EPS estimates for OKYO Pharma in a research note issued on Wednesday, October 16th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.11) per share for the quarter, down from their prior estimate of ($0.09). HC Wainwright currently has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for OKYO Pharma’s current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for OKYO Pharma’s Q4 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.40) EPS.

OKYO Pharma Stock Up 5.1 %

NASDAQ OKYO opened at $1.03 on Monday. The firm’s fifty day moving average price is $1.04 and its two-hundred day moving average price is $1.24. OKYO Pharma has a fifty-two week low of $0.81 and a fifty-two week high of $2.12.

OKYO Pharma Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.